# VivoSim Labs, INC.: overview VIVS · Nasdaq · CIK 1497253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/vivs.md) · [Financials](/companies/vivs/financials.md) · [Filings](/companies/vivs/filings.md) · [Insiders](/companies/vivs/insiders.md) Latest reported revenue: [$18.0k](/filings/0001193125-26-346820.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-346820). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [30.0](/filings/0001193125-25-269483.md) | [24.0](/filings/0001193125-26-046520.md) | [51.0 d](/filings/0001193125-26-303316.md) | [37.0](/filings/0001193125-26-346820.md) | [28.0](/filings/0001193125-25-269483.md) | [26.0](/filings/0001193125-26-046520.md) | [40.0 d](/filings/0001193125-26-303316.md) | [18.0](/filings/0001193125-26-346820.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8693.3%)](/filings/0001193125-25-269483.md) | [(14450.0%)](/filings/0001193125-26-046520.md) | [(6184.3%) d](/filings/0001193125-26-303316.md) | [(7878.4%)](/filings/0001193125-26-346820.md) | [(9410.7%)](/filings/0001193125-25-269483.md) | [(10576.9%)](/filings/0001193125-26-046520.md) | [(7967.5%) d](/filings/0001193125-26-303316.md) | [(15327.8%)](/filings/0001193125-26-346820.md) | | Net margin | % | [(8496.7%)](/filings/0001193125-25-269483.md) | [(14362.5%)](/filings/0001193125-26-046520.md) | [13435.3% d](/filings/0001193125-26-303316.md) | [(7683.8%)](/filings/0001193125-26-346820.md) | [(9089.3%)](/filings/0001193125-25-269483.md) | [(10350.0%)](/filings/0001193125-26-046520.md) | [(14410.0%) d](/filings/0001193125-26-303316.md) | [(7433.3%)](/filings/0001193125-26-346820.md) | | Diluted EPS | $ per share | [(1.68)](/filings/0001193125-25-269483.md) | [(2.28)](/filings/0001193125-26-046520.md) | not reported | [(1.14)](/filings/0001193125-26-346820.md) | [(0.98)](/filings/0001193125-25-269483.md) | [(1.03)](/filings/0001193125-26-046520.md) | not reported | [(0.25)](/filings/0001193125-26-346820.md) | | Free cash flow | $k | [(2,655) d](/filings/0001193125-25-269483.md) | [(1,801) d](/filings/0001193125-26-046520.md) | [(2,035) d](/filings/0001193125-26-303316.md) | [(3,940)](/filings/0001193125-26-346820.md) | [(2,378) d](/filings/0001193125-25-269483.md) | [(2,271) d](/filings/0001193125-26-046520.md) | [(2,238) d](/filings/0001193125-26-303316.md) | [(3,236)](/filings/0001193125-26-346820.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.5](/filings/0000950170-23-032889.md) | [0.4](/filings/0000950170-24-067301.md) | [0.1](/filings/0000950170-25-082312.md) | [0.1](/filings/0001193125-26-303316.md) | [0.1](/filings/0001193125-26-303316.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(765.3%)](/filings/0000950170-23-032889.md) | [(4792.2%)](/filings/0000950170-24-067301.md) | [(13840.4%)](/filings/0000950170-25-082312.md) | [(8761.1%)](/filings/0001193125-26-303316.md) | [(8768.7%)](/filings/0001193125-26-303316.md) | | Net margin | % | [(763.2%)](/filings/0000950170-23-032889.md) | [(4664.6%)](/filings/0000950170-24-067301.md) | [(13459.6%)](/filings/0000950170-25-082312.md) | [(1727.8%)](/filings/0001193125-26-303316.md) | [(10567.2%)](/filings/0001193125-26-303316.md) | | Diluted EPS | $ per share | [(1.32)](/filings/0000950170-23-032889.md) | [(1.98)](/filings/0000950170-24-067301.md) | [(19.25)](/filings/0000950170-25-082312.md) | [(1.70)](/filings/0001193125-26-303316.md) | [(5.35)](/filings/0001193125-26-303316.md) | | Free cash flow | $m | [(8.9)](/filings/0000950170-23-032889.md) | [(12.8)](/filings/0000950170-24-067301.md) | [(14.7)](/filings/0000950170-25-082312.md) | [(9.5)](/filings/0001193125-26-303316.md) | [(10.8)](/filings/0001193125-26-303316.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vivs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $27.8k | 25,976 | | Reduced −10,874 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $19.8k | 18,500 | | New +18,500 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.4k | 15,371 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.6k | 11,817 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $7.5k | 7,003 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $5.6k | 5,249 | | Added +2,941 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $236 | 221 | | Unchanged | | [Larson Financial Group LLC](/funds/1731061.md) | 2026-06-30 | $178 | 166 | | Unchanged | | [ALBION FINANCIAL GROUP /UT](/funds/1054677.md) | 2026-06-30 | $171 | 159 | | Unchanged | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $119 | 111 | | Unchanged | ## Recent filings [All 817 filings](/companies/vivs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 20:05 ET | [8-K](/filings/0001193125-26-424061.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-424061 | | 2026-10-06 | 20:05 ET | [8-K](/filings/0001193125-26-415542.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-415542 | | 2026-08-21 | 20:05 ET | [8-K](/filings/0001193125-26-361085.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001193125-26-361085 | | 2026-08-21 | 20:02 ET | [DEF 14A](/filings/0001193125-26-361066.md) | Proxy statement, period 2026-09-30 | 0001193125-26-361066 | | 2026-08-12 | 20:06 ET | [10-Q](/filings/0001193125-26-346820.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346820 | | 2026-08-06 | 12:05 ET | [8-K](/filings/0001193125-26-336844.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336844 | | 2026-07-31 | 20:16 ET | [S-1](/filings/0001193125-26-328613.md) | Registration statement | 0001193125-26-328613 | | 2026-07-30 | 20:12 ET | [8-K](/filings/0001193125-26-326139.md) | 5.08 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-326139 | | 2026-07-24 | 20:07 ET | [8-K](/filings/0001213900-26-081377.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-081377 | | 2026-07-17 | 12:45 ET | [8-K](/filings/0001193125-26-306849.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-306849 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001193125-26-303316.md), filed Jul 14, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c5d54ed5-4535-4c48-bd49-8f5ace86cb6f) ## About the filer - CIK: 1497253 - Tickers: VIVS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.